Winning a North American client, WuXi Biologics aims to be top global vaccine supplier

2 December 2019

By Wang Fangqing

Wuxi Biologics’ (HK: 2269) vaccine arm WuXi Vaccines (WV) expects to become a giant global vaccine supplier with its $240 million investment in the vaccine facility in Ireland last week, said the WuXi Vaccines chairman Chris Chen at a press meeting held on November 29 in Shanghai. The facility, expected to start operation in 2022, has an annual capacity of about 40 to 60 million vials.

“The reason we promised such a big investment for this North American client is that we are confident about the growth of the global vaccine market,” Dr Chen said. He gave examples of Merck & Co’s (NYSE: MRK) HPV vaccine Gardasil 9 and GlaxoSmithKline’s (LSE: GSK) shingles vaccine Shingrix.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK